Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · Real-Time Price · USD
7.29
+0.07 (0.97%)
Jul 30, 2025, 11:29 AM - Market open
Lifecore Biomedical Stock Forecast
Stock Price Forecast
The 4 analysts that cover Lifecore Biomedical stock have a consensus rating of "Buy" and an average price target of $8, which forecasts a 9.74% increase in the stock price over the next year. The lowest target is $6 and the highest is $10.
Price Target: $8 (+9.74%)
Analyst Consensus: Buy
* Price targets were last updated on Jan 3, 2025.
Analyst Ratings
The average analyst rating for Lifecore Biomedical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | May 21, 2025 |
| Stephens & Co. | Stephens & Co. | Hold Reiterates $6 | Hold | Reiterates | $6 | -17.70% | Jan 3, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $8 → $10 | Strong Buy | Maintains | $8 → $10 | +37.17% | Nov 22, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +9.74% | Sep 5, 2024 |
| Barrington Research | Barrington Research | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Aug 28, 2024 |
Financial Forecast
Revenue This Year
130.36M
from 128.26M
Increased by 1.64%
Revenue Next Year
134.15M
from 130.36M
Increased by 2.91%
EPS This Year
-1.36
from 0.32
EPS Next Year
-0.71
from -1.36
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 134.8M | 143.6M | 165.1M | |||
| Avg | 130.4M | 134.2M | 153.3M | |||
| Low | 124.5M | 126.3M | 143.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 5.1% | 10.1% | 23.0% | |||
| Avg | 1.6% | 2.9% | 14.3% | |||
| Low | -2.9% | -3.1% | 6.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -1.39 | -0.64 | -0.42 | |
| Avg | -1.36 | -0.71 | -0.41 | |
| Low | -1.31 | -0.77 | -0.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.